Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.

Key facts

Study ID

NCT00030849

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-10-01

Expected to finish

2009-12-01

Last updated by the study team

2013-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Abramson Cancer Center of the University of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.